Sept. 20, 2005 (Atlanta) — Results from the STAR trial, comparing two new-generation antimuscarinics solifenacin and tolterodine extended release (ER), suggest that solifenacin is superior in ...

The Food and Drug Administration (FDA) has approved Vesicare LS (solifenacin succinate; Astellas Pharma) oral suspension for the treatment of neurogenic detrusor overactivity (NDO) in pediatric ...

Astellas Pharma announced results from the Phase 3b BESIDE trial with solifenacin (SOLI) with mirabegron (MIRA) as an add-on therapy in incontinent overactive bladder (OAB) patients.

Research Highlight Published: 04 May 2016 Incontinence Adding mirabegron to solifenacin improves patient outcomes Peter Sidaway Nature Reviews Urology 13, 299 (2016) Cite this article ...

Solifenacin (VESIcare) generic is a urinary antispasmodic agent, prescribed for overactive bladder with or without incontinence. It works by blocking the action of certain chemicals in the body to ...

The FDA approved mirabegron, a beta-3 adrenergic agonist, for OAB in June 2012. The FDA approved solifenacin succinate, a muscarinic antagonist, as a monotherapy for the disorder in November 2004.

The proportions of treatment responders in the peroneal eTNM group compared with the solifenacin group were: 87% vs 74% for Patient Perception of Intensity of Urgency Scale (PPIUS) grade 3 urgency ...

The agreed maximum selling prices for Solifenacin Canon have been reduced by more than 15% relative to the registered prices for the reference drug of foreign production Vesicar. So, the price for a ...